×
About 128 results

ALLMedicine™ Fibrolamellar Carcinoma Center

Research & Reviews  45 results

Fibrolamellar carcinoma: An entity all its own.
https://doi.org/10.1016/j.currproblcancer.2021.100770
Current Problems in Cancer; O'Neill AF, Church AJ et. al.

Jul 17th, 2021 - Fibrolamellar carcinoma (FLC) is a rare malignant entity arising from the liver and primarily affecting patients in late adolescence and young adulthood. FLC tumors are characterized by their unique histologic features and an only recently discove...

Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient D...
https://doi.org/10.1158/2159-8290.CD-20-0872
Cancer Discovery; Lalazar G, Requena D et. al.

Jun 15th, 2021 - To repurpose therapeutics for fibrolamellar carcinoma (FLC) we developed and validated patient-derived xenografts (PDX) from surgical resections. Most agents used clinically, and inhibitors of oncogenes overexpressed in FLC showed little efficacy ...

Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with H...
https://doi.org/10.1159/000513358
Oncology Gottlieb S, O'Grady C et. al.

Mar 10th, 2021 - There are no standard systemic therapies for the treatment of fibrolamellar carcinoma (FLC), as surgery remains the only definitive option. We share our experiences using systemic "triple therapy" (TT) with 5-fluorouracil, interferon, and nivoluma...

Fibrolamellar carcinoma: Challenging the challenge.
https://doi.org/10.1016/j.ejca.2020.06.035
European Journal of Cancer (Oxford, England : 1990); Lamarca A, Frizziero M et. al.

Aug 9th, 2020 - Fibrolamellar carcinoma (FLC) is a rare and poorly understood malignancy, which seems to be more prevalent in young patients compared with conventional hepatocellular carcinoma (HCC). Performing prospective clinical trials recruiting patients diag...

Molecular profiling and analysis of genetic aberrations aimed at identifying potential ...
https://doi.org/10.1002/cncr.32960
Cancer El Dika I, Bowman AS et. al.

Jul 14th, 2020 - Fibrolamellar carcinoma (FLC) is a rare primary liver cancer of young adults. A functional chimeric transcript resulting from the in-frame fusion of the DNAJ homolog, subfamily B, member 1 (DNAJB1), and the catalytic subunit of protein kinase A (P...

see more →

Clinicaltrials.gov  3 results

A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02234986

Sep 5th, 2018 - Primary Objective: • To determine the 6-month progression free survival (PFS6) rate when patients with advanced fibrolamellar carcinoma (FLC) are treated with daily oral ENMD 2076 Secondary Objectives: To evaluate the overall response rate using R...

Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma
https://clinicaltrials.gov/ct2/show/NCT01215565

Mar 12th, 2014 - Fibrolamellar hepatocellular carcinoma is variant rare of hepatocellular carcinoma witch distinct clinical, histological and prognostic features from conventional hepatocellular carcinoma. This entity typically occurs in young adults with no under...

Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer
https://clinicaltrials.gov/ct2/show/NCT00899002

Apr 9th, 2013 - OBJECTIVES: To characterize, at a molecular level, archived samples of tissue from young patients with fibrolamellar carcinoma and hepatocellular carcinoma in non-cirrhotic livers matched for age and sex. To perform genomic analysis on these tissu...

see more →

News  3 results

MicroRNA-375 may be key to fibrolamellar carcinoma
https://www.mdedge.com/gihepnews/article/198920/liver-disease/microrna-375-may-be-key-fibrolamellar-carcinoma?channel=69
Will Pass, MDedge News

Apr 15th, 2019 - Up-regulation of microRNA-375 may be a future therapeutic strategy for patients with fibrolamellar carcinoma (FLC), according to investigators. Analysis of primary FLC tumors showed that microRNA-375 was the most abnormal microRNA, down-regulated.

Angiogenic kinase inhibitor receives orphan drug designation for hepatocellular carcinoma
https://www.mdedge.com/hematology-oncology/article/84411/gastroenterology/angiogenic-kinase-inhibitor-receives-orphan-drug
Lora T. McGlade

Jul 10th, 2014 - ENMD-2076, an oral Aurora A/angiogenic kinase inhibitor has received an orphan drug designation from the Food and Drug Administration to treat hepatocellular carcinoma, according to a statement issued by the manufacturer on July 7. With that statu.

38 Year Old Female With Worst Headache of Life
https://www.medscape.com/viewarticle/475293

May 17th, 2004 - Summary 38 year old female with worst headache of life. (Enlarge Image) (Enlarge Image) (Enlarge Image) (Enlarge Image) (Enlarge Image) A tumor of the liver associated with prior exposure to Thorotrast: Hemangioma Angiosarcoma FNH Fibrolamellar ca...

see more →